VRDN vs. OPCH, RDNT, BTSG, SHC, SGRY, CON, PRVA, WGS, ADUS, and PGNY
Should you be buying Viridian Therapeutics stock or one of its competitors? The main competitors of Viridian Therapeutics include Option Care Health (OPCH), RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Surgery Partners (SGRY), Concentra Group Holdings Parent (CON), Privia Health Group (PRVA), GeneDx (WGS), Addus HomeCare (ADUS), and Progyny (PGNY). These companies are all part of the "healthcare" industry.
Viridian Therapeutics vs. Its Competitors
Option Care Health (NASDAQ:OPCH) and Viridian Therapeutics (NASDAQ:VRDN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.
Option Care Health presently has a consensus price target of $35.50, indicating a potential upside of 20.46%. Viridian Therapeutics has a consensus price target of $37.56, indicating a potential upside of 114.73%. Given Viridian Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Viridian Therapeutics is more favorable than Option Care Health.
In the previous week, Option Care Health had 8 more articles in the media than Viridian Therapeutics. MarketBeat recorded 10 mentions for Option Care Health and 2 mentions for Viridian Therapeutics. Option Care Health's average media sentiment score of 1.84 beat Viridian Therapeutics' score of 1.81 indicating that Option Care Health is being referred to more favorably in the media.
Option Care Health has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Option Care Health, indicating that it is currently the more affordable of the two stocks.
Option Care Health has a net margin of 4.12% compared to Viridian Therapeutics' net margin of -102,092.39%. Option Care Health's return on equity of 16.90% beat Viridian Therapeutics' return on equity.
98.1% of Option Care Health shares are owned by institutional investors. 0.6% of Option Care Health shares are owned by insiders. Comparatively, 1.6% of Viridian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Option Care Health has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.
Summary
Option Care Health beats Viridian Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Viridian Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viridian Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VRDN) was last updated on 7/24/2025 by MarketBeat.com Staff
Free VRDN Stock Alerts